AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
The immunology portfolio generated $6.97 billion in sales, up 2.3% on a reported basis or 3.5% on an operational basis.On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
艾伯维公司（NYSE:ABBV）周四发布了第二季度每股收益2.65美元，同比下降8.9％，超过2.57美元的共识。
Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.
净收入达到144.6亿美元，上涨了4.3％，超过了140.3亿美元的共识。销售收入在运营基础上上涨了5.6％。
Also Read: AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock.
此外阅读：艾伯维公司的帕金森病疗法遭遇FDA障碍。
The immunology portfolio generated $6.97 billion in sales, up 2.3% on a reported basis or 3.5% on an operational basis.
免疫学产品组合表现出697亿美元的销售收入，按报告基础上升2.3％或按运营基础上升3.5％。
- Humira revenues were $2.81 billion (down 29.8%), Skyrizi sales reached $2.73 billion (up 44.8%), and Rinvoq revenues were $1.43 billion (up 55.8%).
- Humira的收入为28.1亿美元（下降29.8％），Skyrizi的销售额达到27.3亿美元（增长44.8％），Rinvoq的收入为14.3亿美元（增长55.8％）。
Oncology product sales were $1.63 billion, up 10.5% or 12.2% on an operational basis.
肿瘤学产品的销售额为1.63亿美元，按运营基础上涨10.5％或12.2％。
- Imbruvica revenues were $833 million (down 8.2%), Venclexta sales increased 11.5% to $637 million, and Elahere's net revenues were $128 million.
- Imbruvica的收入为8330万美元（下降8.2％），Venclexta的销售额增长11.5％，为6370万美元，而Elahere的净收入为1.28亿美元。
Neuroscience revenues reached $2.16 billion, up 14.7% on a reported basis or 15.2% on an operational basis.
神经科学收入达21.6亿美元，按报告基础是上涨14.7％或按运营基础上涨15.2％。
- Botox Therapeutic sales were $814 million, up 8.7%. Aesthetics portfolio sales reached $1.39 billion, up 0.5%. Global Botox Cosmetic revenues were $729 million, up 6.4%.
- 肉毒毒素治疗销售额为8.14亿美元，增长8.7％。美容产品组合销售收入达13.9亿美元，上涨0.5％。全球肉毒毒素化妆品的销售收入为7.29亿美元，上涨6.4％。
Citing BMO Capital Markets analyst Reuters noted that the strong results show "the command AbbVie has over its commercial business and their impressive ability to guide through" the loss of exclusivity for Humira.
引用BMO Capital Markets的分析师路透社指出，良好的业绩表明艾伯维公司对其商业业务的掌控力以及在Humira专利失效方面的卓越能力。
Guidance: AbbVie raised its 2024 adjusted EPS guidance from $10.61-$10.81 to $10.71-$10.91 versus consensus of $10.78, which includes an unfavorable impact of $0.60/share related to acquired IPR&D and milestones expense.
指引：艾伯维公司将其2024财年每股调整后的EPS指引从10.61美元至10.81美元上调至10.71美元至10.91美元，预估市场预期为10.78美元，其中包括与收购的IPR＆D和里程碑费用相关的不利影响为每股0.6美元/股。
In the company conference call, AbbVie announced it is discontinuing further development of the experimental Alzheimer's drug ABBV-916 as a standalone antibody.
在公司电话会议上，艾伯维公司宣布将停止独立抗体ABBV-916试验性阿尔茨海默病药物的进一步开发。
Price Action: ABBV stock is down 5.14% at $185.26 at the last check on Thursday.
股价表现：周四下跌5.14％，报185.26美元。
- AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case.
- 艾伯维公司就长期的AndroGel案件向最高法院寻求律师-客户特权。
Photo via Shutterstock
图片来自shutterstock。